Non-Alcoholic Fatty Liver Disease Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Increase in the NASH-affected population
   3. Market Restraints
      1. Limited Treatment Options
      2. Diagnostic Challenges
   4. Market Opportunities
      1. Development of Novel Therapies with Minimum Side Effects
   5. Market Trends
      1. Increasing Focus on Precision Medicine
      2. Rising Adoption of Digital HealthSolutions
5. MARKET SEGMENTATION
   1. By Drug Type
      1. Vitamin E and Pioglitazone
      2. Ocaliva
      3. Elafibranor
      4. Elonsertib and Cenicriviroc
      5. Obeticholic Acid
      6. Others
   2. By Sales Channel
      1. Hospital Pharmacy
      2. Online Providers
      3. Retail Pharmacy
   3. By Disease Cause
      1. Hypertension
      2. Heart Disease
      3. High Blood Lipid
      4. Type 2 Diabetes
      5. Obesity
   4. By End User
      1. Hospitals
      2. Clinics
      3. Homecare Settings
   5. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. AbbVie Inc.
      2. Algernon Pharmaceuticals
      3. Allergan plc
      4. Boehringer Ingelheim International GmbH.
      5. Bristol Myers Squibb Company
      6. Celerion
      7. Conatus Pharmaceuticals Inc.
      8. Enzo Biochem Inc.
      9. Galmed Pharmaceuticals Ltd
      10. Gemphire
      11. Genfit SA
      12. Gilead Sciences, Inc.
      13. Immuron
      14. Intercept Pharmaceuticals, Inc.
      15. Novartis AG
      16. NuSirt Biopharma
      17. Novo Nordisk A/S
      18. Pfizer Inc.
      19. Perspectum Diagnostics
      20. Shire
      21. Zydus Pharmaceuticals, Inc.
   2. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Non-Alcoholic Fatty Liver Diseasemarket?

The global market of Non-Alcoholic Fatty Liver Disease is projected to reach USD 13.95Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Non-Alcoholic Fatty Liver Disease market?

The global Non-Alcoholic Fatty Liver Disease market has an estimated annual growth rate of 24.18%. 

Q.3. What are the recent trends of Non-Alcoholic Fatty Liver Disease market?

Increasing focus on precision medicine and rising adoption of digital healthsolutionsare some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Non-Alcoholic Fatty Liver Disease ?

The major companies profiled in this report include AbbVie Inc., Algernon Pharmaceuticals, Allergan plc, Boehringer Ingelheim International GmbH., Bristol Myers Squibb Company, Celerion, Conatus Pharmaceuticals Inc., Enzo Biochem Inc., Galmed Pharmaceuticals Ltd, Gemphire, Genfit SA, Gilead Sciences, Inc., Immuron, Intercept Pharmaceuticals, Inc., Novartis AG, NuSirt Biopharma, Novo Nordisk A/S, Pfizer Inc., Perspectum Diagnostics, Shire, Zydus Pharmaceuticals, Inc., among others. 

Q.5. Which region is estimated to held highest CAGR inNon-Alcoholic Fatty Liver Diseasemarket?

North America is estimated to hold biggest share in the market for Non-Alcoholic Fatty Liver Disease.